epharma logo



Red yest rice, produced by the fermentation of rice due to the action of a fungus, Monascus purpureus, showed favourable effects on plasma cholesterol, due to its active principle monacolin K, corresponding to the chemical structure of lovastatin;

Mulberry extract has hypoglicaemic activity and contributes to maintain normal blood glucose levels;

Banaba extract helps to mantain normal blood glucose levels and contributes to normal glucose metabolism. It participates to the management of body weight: it is an adjuvant during a hypocaloric diet for the control weight;

Chromium helps to maintain normal blood glucose levels, it contributes to normal glucose-insulin metabolism and can delay increased level of blood glucose.
It promotes carbohydrates and lipid catabolism, helping in body weight maintaining. 


LIPIDATIN® favours the control of plasma cholesterol and triglycerides and helps in maintaining normal levels of glycaemia, as integration of an adequate and varied diet. It contributes to control body weight.



LIPIDATIN® is a food supplement available in soluble granules (in sachet) with an antydislipemic, hypoglicaemic and body weight management effect.



1 sachet of LIPIDATIN® per day is recommended. The soluble granules should be dissolved in a glass of water.

- gluten free
- lactose free
- sugar free


Ingredients Content for
% RNV*
Monacolin K from Red yeast rice
(Oryza sativa L. Monascus purpureus) Went., seed)**
10 mg  
Mulberry (Morus alba leaf) extract min 1% deoxynojirimycin 4 mg  
Banaba (Lagerstroemia speciosa L. leaf) dry extract
(min 1% corosolic acid)
20 mg  
Chromium 40 µg 100%

(*) % Reference Nutrient Values - (**) Rice Kolin TM



Hypolipidemic efficacy and safety of Lipidatin® have been under evaluation in a preliminary, observational clinical study, in which 30 subjects presenting abnormal values of cholesterolemia (tot chol >190 mg/dL or LDL chol >150 mg/dL) not requiring a hypolipidemic pharmacologic therapy, were enrolled [De Leo et al. 2017].

LIPIDATIN® is administered orally at the dose of 1 sachet/day for 12 weeks with evaluation of the lipidic and glucidic profile at 6 and 12 weeks after the start of treatment.
The following blood lipid parameters are evaluated: tot chol, HDK chol, LDL chol, triglycerides, glycaemia, insulin, weight and wrist circumference.

Phytosurveillance: any adverse reaction or unwanted event is recorded in the Case report form, specifying severity, duration, onset time, relationship with the treatment and the action taken.